Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, February 15th. Analysts expect Ultragenyx Pharmaceutical to post earnings of ($1.65) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.
Ultragenyx Pharmaceutical Trading Up 0.0 %
RARE stock opened at $46.74 on Tuesday. The stock has a fifty day moving average of $45.49 and a 200-day moving average of $40.06. Ultragenyx Pharmaceutical has a fifty-two week low of $31.52 and a fifty-two week high of $54.98.
Analysts Set New Price Targets
A number of equities analysts have weighed in on the stock. StockNews.com upgraded shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Friday, December 8th. Morgan Stanley cut their price objective on shares of Ultragenyx Pharmaceutical from $90.00 to $84.00 and set an “overweight” rating for the company in a report on Friday, November 3rd. Wells Fargo & Company started coverage on shares of Ultragenyx Pharmaceutical in a report on Friday, December 8th. They set an “overweight” rating and a $72.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $114.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, January 19th. Finally, Robert W. Baird boosted their price objective on Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the company an “outperform” rating in a research note on Tuesday, January 30th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus target price of $90.60.
Institutional Investors Weigh In On Ultragenyx Pharmaceutical
Several large investors have recently added to or reduced their stakes in RARE. Delphia USA Inc. purchased a new stake in shares of Ultragenyx Pharmaceutical in the 4th quarter valued at about $256,000. Stifel Financial Corp purchased a new stake in Ultragenyx Pharmaceutical in the second quarter valued at approximately $254,000. Prelude Capital Management LLC bought a new stake in Ultragenyx Pharmaceutical during the third quarter valued at approximately $253,000. MetLife Investment Management LLC purchased a new position in Ultragenyx Pharmaceutical in the 1st quarter worth approximately $252,000. Finally, Echo Street Capital Management LLC bought a new position in shares of Ultragenyx Pharmaceutical in the 1st quarter worth $234,000. Institutional investors own 96.37% of the company’s stock.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
- Five stocks we like better than Ultragenyx Pharmaceutical
- How to Invest in Hotel Stocks
- 3 attractive stocks that insiders are buying
- Market Cap Calculator: How to Calculate Market Cap
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- CD Calculator: Certificate of Deposit Calculator
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.